Literature DB >> 33572943

Prevalence of Rubella Antibodies among Fertile Women in the West of Romania, 18 Years after the Implementation of Immunization.

Florin Gorun1, Daniel Malita2, Ioana Ciohat3, Tatjana Vilibic-Cavlek4,5, Horea Feier6, Irena Tabain4, Marius Craina1, Octavian Cretu7, Dan Navolan1.   

Abstract

Seronegative women are susceptible to primary rubella virus (RV) infection during pregnancy, which can cause fetal damage. Vaccination represents the main strategy in rubella prevention. The aim of this study was to analyze changes in the rubella seroprevalence and identify populations with a high susceptibility to RV. A cross-sectional study was performed on 6914 Caucasian fertile women who had Toxoplasma gondii, other viruses, Rubella, Cytomegalovirus, and the herpes simplex virus (TORCH) screening in two distinct periods-1452 at the Timișoara Municipal Hospital, Romania (Group 1: 2008-2010) and 5462 at the laboratory Bioclinica S.A., Timișoara, Romania (Group 2: 2015-2018). The RV seroprevalence decreased (Group 1 versus Group 2; 94.1% (92.7-95.2) versus 91.4% (90.6-92.1), OR = 0.76 (p = 0.0007)). According to the year of birth and eligibility to vaccination program, RV seroprevalence rates were 82.4% (76.8-86.8)/1997-2004, 85.4% (80.5-89.3)/1995-1996, 90.1% (89.0-91.1)/<1989, and 95.8% (94.7-96.6)/1989-1994. No significant difference in the RV seropositivity according to the place of residence was found. The overall RV susceptibility increased from 2008-2010 to 2015-2018. The highest susceptibility was found in women born between 1997-2004 eligible for measles-mumps-rubella (MMR) vaccine through the family practice system and the lowest in women born between 1989-1994 eligible for monovalent rubella vaccine conducted in schools.

Entities:  

Keywords:  Romania; epidemiology; pregnant women; rubella virus; vaccine

Year:  2021        PMID: 33572943      PMCID: PMC7912329          DOI: 10.3390/vaccines9020104

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  20 in total

Review 1.  Rubella and pregnancy: diagnosis, management and outcomes.

Authors:  Elise Bouthry; Olivier Picone; Ghada Hamdi; Liliane Grangeot-Keros; Jean-Marc Ayoubi; Christelle Vauloup-Fellous
Journal:  Prenat Diagn       Date:  2014-09-16       Impact factor: 3.050

2.  Vaccine hesitancy: Definition, scope and determinants.

Authors:  Noni E MacDonald
Journal:  Vaccine       Date:  2015-04-17       Impact factor: 3.641

3.  Rubella is eliminated from the Americas.

Authors:  Tony Kirby
Journal:  Lancet Infect Dis       Date:  2015-07       Impact factor: 25.071

4.  Global seroprevalence of rubella among pregnant and childbearing age women: a meta-analysis.

Authors:  E Pandolfi; F Gesualdo; C Rizzo; A Bella; E Agricola; P Mastroiacovo; A E Tozzi
Journal:  Eur J Public Health       Date:  2017-06-01       Impact factor: 3.367

5.  Eliminating congenital rubella: a seroepidemiological study on women of childbearing age and MMR vaccine coverage in newborns.

Authors:  D Lo Giudice; G Cannavò; A Capua; O C Grillo; V La Fauci; A Puliafito; D Sindoni; R Squeri; S Calimeri
Journal:  J Prev Med Hyg       Date:  2009-12

Review 6.  The MMR Vaccine and Autism.

Authors:  Frank DeStefano; Tom T Shimabukuro
Journal:  Annu Rev Virol       Date:  2019-04-15       Impact factor: 10.431

7.  Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets.

Authors:  Anthony Nardone; Annedore Tischer; Nick Andrews; Jo Backhouse; Heidi Theeten; Nina Gatcheva; Marios Zarvou; Bohumir Kriz; Richard G Pebody; Kalman Bartha; Darina O'Flanagan; Dani Cohen; Arnis Duks; Algirdas Griskevicius; Joel Mossong; Christopher Barbara; Adrianna Pistol; Margareta Slaciková; Katarina Prosenc; Kari Johansen; Elizabeth Miller
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

Review 8.  Vaccine Adverse Events: Separating Myth from Reality.

Authors:  Jeanne P Spencer; Ruth H Trondsen Pawlowski; Stephanie Thomas
Journal:  Am Fam Physician       Date:  2017-06-15       Impact factor: 3.292

Review 9.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.